Explore

Trendline Trendline
Corcept Therapeutics Faces Legal Action Over FDA Rejection of Relacorilant

Corcept Therapeutics Faces Legal Action Over FDA Rejection of Relacorilant

Corcept Therapeutics Faces Legal Action Over FDA Rejection of Relacorilant
Trendline Trendline
Cartherics and Catalent Expand License Agreement to Advance Cell Therapy Products

Cartherics and Catalent Expand License Agreement to Advance Cell Therapy Products

Cartherics and Catalent Expand License Agreement to Advance Cell Therapy Products
Trendline Trendline
Corcept Therapeutics Faces Class Action Lawsuit Over Misleading Investors on FDA Approval

Corcept Therapeutics Faces Class Action Lawsuit Over Misleading Investors on FDA Approval

Corcept Therapeutics Faces Class Action Lawsuit Over Misleading Investors on FDA Approval
Trendline Trendline
ReAlta Life Sciences Secures $40 Million to Advance Pegtarazimod for Neonatal Brain Injury

ReAlta Life Sciences Secures $40 Million to Advance Pegtarazimod for Neonatal Brain Injury

ReAlta Life Sciences Secures $40 Million to Advance Pegtarazimod for Neonatal Brain Injury
Trendline Trendline
Avalyn Pharma Files for IPO to Advance Pulmonary Fibrosis Treatments

Avalyn Pharma Files for IPO to Advance Pulmonary Fibrosis Treatments

Avalyn Pharma Files for IPO to Advance Pulmonary Fibrosis Treatments
Trendline Trendline
Sensei Biotherapeutics to Present at Needham Virtual Healthcare Conference

Sensei Biotherapeutics to Present at Needham Virtual Healthcare Conference

Sensei Biotherapeutics to Present at Needham Virtual Healthcare Conference
Trendline Trendline
Cingulate's ADHD Drug Faces FDA Manufacturing Review, No Safety Concerns Reported

Cingulate's ADHD Drug Faces FDA Manufacturing Review, No Safety Concerns Reported

Cingulate's ADHD Drug Faces FDA Manufacturing Review, No Safety Concerns Reported
Trendline Trendline
Phanes Therapeutics Expands Clinical Study of Spevatamig for Biliary Tract Cancer Treatment

Phanes Therapeutics Expands Clinical Study of Spevatamig for Biliary Tract Cancer Treatment

Phanes Therapeutics Expands Clinical Study of Spevatamig for Biliary Tract Cancer Treatment
Trendline Trendline
Insmed Halts Development of Skin Treatment Amid Competitive Advances

Insmed Halts Development of Skin Treatment Amid Competitive Advances

Insmed Halts Development of Skin Treatment Amid Competitive Advances
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion
Trendline Trendline
enGene Announces Corporate Name Change to enGene Therapeutics Inc. Reflecting Commercial Transition

enGene Announces Corporate Name Change to enGene Therapeutics Inc. Reflecting Commercial Transition

enGene Announces Corporate Name Change to enGene Therapeutics Inc. Reflecting Commercial Transition
Trendline Trendline
enGene Therapeutics Inc. Announces Name Change Reflecting Transition to Commercial Organization

enGene Therapeutics Inc. Announces Name Change Reflecting Transition to Commercial Organization

enGene Therapeutics Inc. Announces Name Change Reflecting Transition to Commercial Organization